D. Desai

A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.

Diansong Zhou, S. Grimm, Mark A. Smith, 2012, British journal of clinical pharmacology.

Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors

A. Seftel, N. Modi, D. Desai, 2006, International Journal of Impotence Research.

Single‐ and Multiple‐Dose Pharmacokinetics of Dapoxetine Hydrochloride, a Novel Agent for the Treatment of Premature Ejaculation

Suneel K. Gupta, N. Modi, D. Desai, 2006, Journal of clinical pharmacology.

The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia: A Proof-of-Principle Study

Mark A. Smith, S. Kanes, R. Litman, 2014, Journal of clinical psychopharmacology.

Safety and Tolerability of Dexmecamylamine (TC-5214) Adjunct to Ongoing Antidepressant Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy: Results of a Long-Term Study

G. Dunbar, D. Hosford, H. Eriksson, 2015, Journal of clinical psychopharmacology.